Bull
$19.80
Scenario price
$20.610
-0.089 (-0.43%)At close
Sabra Health Care REIT Inc operates as a self-administered, self-managed real estate investment trust that, through its subsidiaries, owns and invests in real estate serving the healthcare industry. The Company's primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. The Company invests primarily in the United States nursing home industry, including skilled nursing and transitional care facilities, the United States and Canadian senior housing industry, which includes independent living, assisted living, memory care and continuing care retirement communities, select behavioral health and addiction treatment centers, and acute care and other hospitals. Its skilled nursing facilities provide services that include daily nursing, therapeutic rehabilitation, social services, activities, housekeeping, nutrition, medication management and administrative services for individuals.
Sabra Health Care REIT Inc is a good buy right now due to its current price of $20.61, which is below the analyst price target of $25, indicating significant upside potential. Additionally, the company has a forward P/E ratio of 32.15, suggesting it is reasonably valued for future earnings growth. The recent announcement of a quarterly dividend of $0.30 reflects stable cash flow and a forward yield of 5.82%, appealing to income-focused investors. However, the main risk is the net loss of $0.10 per share reported in Q2 2026, which may affect investor confidence in the short term.
Raymond James
—
2026-08-06
Raymond James
2026-08-06
Price Target
—
Deutsche Bank
$25
2026-07-22
Deutsche Bank
2026-07-22
Price Target
$25
Baird
$23
2026-07-22
Baird
2026-07-22
Price Target
$23
Citizens
$25
2026-07-22
Citizens
2026-07-22
Price Target
$25
UBS
$21
2026-07-08
UBS
2026-07-08
Price Target
$21
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Sabra Health Care REIT Q2 2026 Earnings Call Highlights

Sabra Health Care Declares Quarterly Dividend of $0.30

Sabra Health Care Reports Q2 2026 Earnings Results

US Reinstates Tariffs Impacting Market Dynamics

Sabra Releases 2025 Sustainability Report Highlighting Key Innovations
Sabra Health Care REIT Inc operates as a self-administered, self-managed real estate investment trust that, through its subsidiaries, owns and invests in real estate serving the healthcare industry. The Company's primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. The Company invests primarily in the United States nursing home industry, including skilled nursing and transitional care facilities, the United States and Canadian senior housing industry, which includes independent living, assisted living, memory care and continuing care retirement communities, select behavioral health and addiction treatment centers, and acute care and other hospitals. Its skilled nursing facilities provide services that include daily nursing, therapeutic rehabilitation, social services, activities, housekeeping, nutrition, medication management and administrative services for individuals. It operates in the Real Estate sector (REAL ESTATE INVESTMENT TRUSTS industry).
Sabra Health Care REIT Inc is a good buy right now due to its current price of $20.61, which is below the analyst price target of $25, indicating significant upside potential. Additionally, the company has a forward P/E ratio of 32.15, suggesting it is reasonably valued for future earnings growth. The recent announcement of a quarterly dividend of $0.30 reflects stable cash flow and a forward yield of 5.82%, appealing to income-focused investors. However, the main risk is the net loss of $0.10 per share reported in Q2 2026, which may affect investor confidence in the short term.
12 analysts cover SBRA: 4 rate it Buy, 7 Hold and 1 Sell. The average price target is 20.83.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.